Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 18, 2020

AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer

By Victoria Smith

AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell lung cancer (NSCLC), regardless of positive Phase III data, in the absence of a consensus on whether data suggesting a survival benefit is required.

The Phase III (NCT02511106) ADAURA study data was presented at the American Society of Clinical Oncology (ASCO) Virtual Meeting plenary session last month. Read more here.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU